Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post on LinkedIn:
“Announcing the 2025 “State of AI in Precision Oncology” Virtual Global Summit.
One of the things I love about my Editor-in-Chief role at AI in Precision Oncology is bringing people together for the very best in curated, practical, “what you need to know” content.
It’s the whole reason I founded this journal.
And each December, our State of AI in Precision Oncology summit proves why this community matters. We’ve drawn 5,000 registrants in prior years – and given this year’s lineup, we may break our own record.
This year’s speakers are doing the actual work of transformation:
Amy Abernethy, MD, PhD co-founded Highlander Health in 2024 after a career marked by changemaking across healthcare systems—from building Flatiron Health’s real-world oncology data platform to serving as principal deputy commissioner at FDA (2019-2021) to leading health initiatives at Verily. She brings the rare perspective of someone who understands how AI must work across regulatory requirements, clinical reality, and industry innovation.
Isaac Kohane , MD, PhD is the inaugural chair of the Department of Biomedical Informatics at Harvard Medical School and founding editor of NEJM AI. We will compare notes on what we’re learning as editors of two major AI medical journals – a conversation between editorial peers who see what’s actually getting submitted, peer-reviewed, and published.
Connie Lehman, MD, PhD is a Professor of Radiology at Mass General Hospital and Harvard Medical School who founded Clairity, Inc. to transform breast cancer screening. She’s one of the world’s foremost experts in transforming breast cancer screening through artificial intelligence.
Elizabeth O’Donnell, MD, DipABLM serves as Director of Early Detection and Prevention of Malignant Conditions at Dana-Farber Cancer Institute, where she’s at the forefront of blood-based cancer screening using advanced data analysis—the kind of liquid biopsy advances that seemed impossible just a few years ago but are now entering clinical practice.
Lucio N. Gordan, MD is President and Managing Physician at Florida Cancer Specialists & Research Institute, leading AI implementation in one of the nation’s largest community cancer practices where most patients actually receive their care. He brings the practical reality of bringing these tools into settings without academic medical center resources.
David Penberthy, MD MBA FACCC is a professor of radiation oncology at UVA, former Association of Cancer Care Centers President, and who closes our summit out by looking into his crystal ball to forecast what cancer care might look like in 2030. What becomes possible when these technologies mature over the next five years?
December 16, 11 AM – 3 PM EST. Virtual. Free.
Four hours of keynote interviews, presentations, and fireside chats. Honest conversations about what’s working, what’s not, and where we go from here.
Won’t you join us? You can’t beat the price.”
More posts featuring Douglas Flora on OncoDaily.